UpDoc announces first FDA-cleared device with a patient-facing LLM, for insulin dosing
On June 25, 2026, UpDoc publicly announced the FDA 510(k) clearance (K253281, granted in December 2025) of UpDoc V1.0. It is prescription software that talks with adults with type 2 diabetes by voice or text and adjusts their insulin within limits set by their physician. The company calls it the first FDA-cleared device to use patient-facing large language models. It says the system is deployed at Cleveland Clinic, Allegheny Health Network and UCSF Health, can order follow-up labs and writes its actions into the EHR. It was cleared as a 510(k) with an insulin dosing program as the predicate device, and it is backed by a small Stanford randomized trial published in JAMA Network Open. STAT reported that the CEO would not say whether the language model itself makes the dosing decisions.
Why it's notable: This is the first regulatory path for an AI that talks directly with patients to adjust a drug between visits, and other developers are likely to follow it. It also leaves open how much of the clinical decision the language model makes and how much fixed dosing rules make.